Major pharmaceutical companies are increasingly investing in psychedelic-based therapeutics, signaling a paradigm shift in mental health treatment. Eli Lilly's strategic acquisition of AtaiBeckley demonstrates institutional confidence in the clinical potential of these compounds for treating depression, PTSD, and other psychiatric disorders. This corporate endorsement reflects growing clinical evidence and regulatory momentum that positions psychedelics as a legitimate medical frontier, moving beyond historical stigma toward evidence-based therapeutic applications.

Summary auto-generated by AI from the original publisher's content. Editorial standards.